



## **Non-Small Cell Lung Cancer Surveillance Medicare Advantage Quick Reference Guide (QRG)**

Cigna has partnered with eviCore® to provide Radiation Therapy Services for your Medicare Advantage patients. eviCore's clinical guidelines have been carefully researched and are continually updated in order to be consistent with the most current evidence-based guidelines and recommendations for the provision of radiation therapy. To avoid potential authorization denials, please follow the quick reference guide below for non-small cell lung cancer surveillance.

### **Surveillance of Stage I and II NSCLC**

- CT Chest with contrast (CPT® 71260) or CT Chest without contrast (CPT® 71250) every 6 months for 2 years and then annually
- Individuals treated with radiation therapy and residual abnormality on imaging may undergo CT Chest every 3 months for the first year after therapy, every 6 months in year 2, annually thereafter

### **Surveillance of Stage III and IV NSCLC**

- CT Chest with contrast (CPT® 71260) or CT Chest without contrast (CPT® 71250) every 3 months

Please contact our Client Services department at [clientservices@evicore.com](mailto:clientservices@evicore.com) with any questions regarding the guidelines.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna HealthCare of South Carolina, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of Arizona, Inc., Cigna HealthCare of St. Louis, Inc., HealthSpring Life & Health Insurance Company, Inc., HealthSpring of Florida, Inc., Bravo Health Mid-Atlantic, Inc., and Bravo Health Pennsylvania, Inc. The Cigna name, logos, and other Cigna marks are owned by Cigna Intellectual Property, Inc. INT\_19\_81783\_C  
10.2019